### NIHR Health Protection Research Unit in Gastrointestinal Infections at University of Liverpool The evolution and international spread of extensively drug-resistant Shigella sonnei

Lewis Mason<sup>1,2</sup>, David R Greig<sup>3</sup>, Lauren A Cowley<sup>4</sup>, Sally R Partridge<sup>5,6,7,8</sup>, Elena Martinez<sup>7,9</sup>, Grace A Blackwell<sup>7,9</sup>, Charlotte E Chong<sup>2</sup>, P. Malaka De Silva<sup>2</sup>, Rebecca J Bengtsson<sup>2</sup>, Jenny L Draper<sup>7,9</sup>, Andrew N Ginn<sup>7,8,9</sup>, Indy Sandaradura<sup>6,7,9</sup>, Eby M Sim<sup>5,6,8</sup>, Jonathan R Iredell<sup>5,6,7,8</sup>, Vitali Sintchenko<sup>5,6,7,8,9,10</sup>, Danielle J Ingle<sup>11</sup>, Benjamin P Howden<sup>11</sup>, Sophie Lefèvre<sup>12</sup>, Elisabeth Njampeko<sup>12</sup>, François-Xavier Weill<sup>12</sup>, Pieter-Jan Ceyssens<sup>13</sup>, Claire Jenkins<sup>3</sup>, Kate S Baker<sup>1,2,\*</sup>


### Abstract

*Shigella sonnei* causes shigellosis, a severe gastrointestinal illness that is sexually transmissible among men who have sex with men (MSM). Multidrug resistance in *S. sonnei* is common and can include resistance to the WHO recommended treatment options, azithromycin, and ciprofloxacin. Recently, an MSM-associated outbreak of extended-spectrum β-lactamase producing, extensively drug resistant *S. sonnei* was reported in the United Kingdom. Here, we aimed to identify the genetic basis, evolutionary history, and international dissemination of the outbreak strain. Our genomic epidemiological analyses of 3,304 isolates from the United Kingdom, Australia, Belgium, France, and the United States of America revealed an internationally connected outbreak carrying a low-fitness cost resistance plasmid, previously observed in travel associated sublineages of *S. flexneri*. Our results highlight the persistent threat of horizontally transmitted antimicrobial resistance and the value of continuing to work towards early and open international sharing of genomic surveillance data.

Tree scale: 100	<b>├──</b> ,──-	bla <sub>CTX-M</sub>
Isolation Year	Travel	mph(A)
2016	Africa	QRDR*3 BAPS

#### Introduction

Shigella sonnei (S. sonnei) causes




**Figure 1. The emergence of an XDR S.** *sonnei* **outbreak in the United Kingdom.** A cgMLST dendrogram (midpoint rooted) of clinical isolates from the UK (n=2,820) and genomic subtype references (n=120) with the scale bar indicating distance in cgMLST alleles. Metadata tracks show patient and genomic features for isolates coloured according to the inlaid keys. Specifically, from inner to outer, the patient data comprises: year of isolation, patient sex, age group, and travel history (for UK isolates only), with missing/unavailable/not determined data shown as white. Genomic features then show: isolate lineage, BAPS clusters (for isolates belonging to the t10.377 cluster only), and the presence of mutations in the Quinolone Resistance Determining Region (QRDR\*3 denotes all three canonical mutations; *gyrA\_D87G*, *gyrA\_S83L* and *parC\_S80I*) and *mph*(A), and *bla*<sub>CTX-M</sub> genes, where white indicates absence of the gene.

shigellosis, a sexually transmissible illness.

- Ciprofloxacin and azithromycin resistant *S. sonnei* recently acquired resistance to ceftriaxone by acquiring a plasmid-borne *bla*<sub>CTX-M-27</sub> gene.
- Our work aimed to investigate the evolution and spread of this extensively drug-resistant (XDR) *S. sonnei.*

# Emergence of XDR S. sonnei in the United Kingdom

- bla<sub>CTX-M-27</sub>-containing isolates are in the BAPS 5 group of the phylogenetic tree.
- Males aged 16 60 who had not reported international travel represented 84% (405/482) of CipR.MSM5, genotype 3.6.1.1.2 isolates in the UK, associated with



sexual transmission.

# International spread of XDR S. sonnei

- XDR S. sonnei in the BAPS 5 group have spread across the UK, Australia, USA, Belgium and France.
- These XDR S. sonnei have retained mph(A), erm(B) and qnrB19, but lost bla<sub>TEM-1</sub>.
- This analysis suggests the CipR.MSM5 isolates carrying bla<sub>CTX-M-27</sub> were circulating intercontinentally across regions historically considered low-risk for shigellosis.

### Conclusion

 It is clear that the emergence of a concerning antimicrobial

**Figure 2.** The evolution and international spread of MSM-associated *XDR S. sonnei*. A midpoint rooted maximum likelihood phylogenetic tree shows the distribution of UK isolates (belonging to both CipR.MSM5 and the t10.377 outbreak cluster, n=468) and relevant related international isolates belonging to CipR.MSM5 (Supplementary Figure 1, n=475). Metadata tracks show year and country (area) of isolation, BAPS subtype, and the presence of selected AMR genes according to the inlaid keys. The scalebar is provided by IQTree,<sup>50</sup> and represents expected number of substitutions per site across a 1,717 bp alignment. Bold branches represent a bootstrap value of  $\geq$  70 out of 100.

resistance phenotype can lead to rapid global dissemination.

 This study highlights the importance of international cooperation and collaboration in genomic surveillance.

#### Author affiliations

<sup>1</sup>NIHR HPRU in Gastrointestinal Infections at University of Everptool., <sup>2</sup> Department of Clinical Infection, Microbiology, and Immunology; Institute for Infection, Veterinary and Ecological Sciences., <sup>3</sup> CJ/DG Gastro and Food Safety (One Health) Division, UK Health Security Agency, London, UK, <sup>4</sup> Milner Centre for Evolution, University of Bath, Bath, United Kingdom., <sup>5</sup> Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, New South Wales, Australia., <sup>6</sup> Western Sydney Local Health District, New South Wales, Australia., <sup>8</sup> Sydney Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>9</sup> New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>9</sup> New South Wales, Health Pathology, New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>9</sup> New South Wales, Australia., <sup>9</sup> New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases Institute, University of Sydney, New South Wales, Australia., <sup>10</sup> Centre for Infectious Diseases, New South Wales, Australia., <sup>11</sup> Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunology, The University of Melbourne, Australia., <sup>12</sup> Institut Pasteur, Université Paris Cité, Unité des Bactéries pathogènes entériques, Centre National de Référence des *Escherichia coli, Shigella* et *Salmonella*, Paris, F-75015, France., <sup>13</sup> Division of Human Bacterial Diseases, Sciensano, Belgium., \* Corresponding author: kb



The research was funded by the National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool in partnership with the UK Health Security Agency (UKHSA), in collaboration with University of Warwick. The views expressed are those of the author(s) and not necessarily the NIHR, the Department of Health and Social Care or the UK Health Security Agency.